NDC 0074-2042

Skyrizi

Risankizumab-rzaa

Skyrizi is a Kit in the Human Prescription Drug category. It is labeled and distributed by Abbvie Inc.. The primary component is .

• Product ID: 0074-2042_05c4dbfd-4d63-4c5f-950b-cca935a753c3
• NDC: 0074-2042
• Product Type: Human Prescription Drug
• Proprietary Name: Skyrizi
• Generic Name: Risankizumab-rzaa
• Dosage Form: Kit
• Marketing Start Date: 2019-04-23
• Marketing End Date: 2023-01-31
• Marketing Category: BLA / BLA
• Application Number: BLA761105
• Labeler Name: AbbVie Inc.
• Active Ingredient Strength: 0
• NDC Exclude Flag: N

Packaging

NDC 0074-2042-02

1 KIT in 1 CARTON (0074-2042-02) * .83 mL in 1 SYRINGE * 1 mL in 1 PACKET

• Marketing Start Date: 2019-04-23
• Marketing End Date: 2023-01-31
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 0074-2042-02 [00074204202]

Skyrizi KIT

• Marketing Category: BLA
• Application Number: BLA761105
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: EA
• Marketing Start Date: 2019-04-23

NDC 0074-2042-71 [00074204271]

Skyrizi KIT

• Marketing Category: BLA
• Application Number: BLA761105
• Product Type: HUMAN PRESCRIPTION DRUG
• Marketing Start Date: 2019-04-23

Drug Details

OpenFDA Data

• SPL SET ID: 7148c8eb-b39e-e20a-6494-a6df82392858
• Manufacturer:
  • AbbVie Inc.

NDC Crossover Matching brand name "Skyrizi" or generic name "Risankizumab-rzaa"

NDC	Brand Name	Generic Name
0074-1050	Skyrizi	risankizumab-rzaa
0074-1065	Skyrizi	Risankizumab-rzaa
0074-1070	Skyrizi	Risankizumab-rzaa
0074-2042	Skyrizi	Risankizumab-rzaa
0074-2100	Skyrizi	risankizumab-rzaa